Recent advances in the treatment of pulmonary hypertension

Hellenic Journal of Cardiology

Volumn 46, Issue 3, 2005, Pages 165-173

  Broberg, Craig ^a   Gatzoulis, Michael ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Advanced therapies; Congenital heart disease; Pulmonary arterial hypertension

Indexed keywords

BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ILOPROST; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; SILDENAFIL; UNIPROST; WARFARIN; ANTIHYPERTENSIVE AGENT; VASODILATOR AGENT;

BLOOD PRESSURE; CLINICAL FEATURE; CONGENITAL HEART DISEASE; DIZZINESS; FLUSHING; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LUNG ARTERY PRESSURE; MEDICAL RESEARCH; NAUSEA; PULMONARY HYPERTENSION; REVIEW; THROMBECTOMY; VOMITING; CHILD; DRUG EFFECT; HEART ATRIUM; HEART SURGERY; HEART VENTRICLE SEPTUM; LUNG TRANSPLANTATION; LUNG WEDGE PRESSURE; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CARDIAC SURGICAL PROCEDURES; CHILD; HEART ATRIA; HEART SEPTUM; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; PROGNOSIS; PULMONARY WEDGE PRESSURE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 24644445270     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Archer S, Rich S: Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 2000; 102: 2781-2791.
2. Farber HW, Loscalzo J: Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
3. Simonneau G, Galie N, Rubin LJ, et al: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
4. Rich S, Dantzker DR, Ayres SM, et al: Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223.
5. D'Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
6. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM: Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167: 580-586.
7. Wensel R, Opitz CF, Anker SD, et al: Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106: 319-324.
8. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
9. Shitrit D, Bendayan D, Bar-Gil-Shitrit A, et al: Significance of a plasma D-dimer test in patients with primary pulmonary hypertension. Chest 2002; 122: 1674-1678.
10. Bustamante-Labarta M, Perrone S, De La Fuente RL, et al: Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr 2002; 15:1160-1164.
11. Nagasaka Y, Akutsu H, Lee YS, Fujimoto S, Chikamori J: Longterm favorable effect of oxygen administration on a patient with primary pulmonary hypertension. Chest 1978; 74: 299-300.
12. Atz AM, Adatia I, Lock JE, Wessel DL: Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33: 813-819.
13. Roberts DH, Lepore JJ, Maroo A, Semigran MJ, Ginns LC: Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001; 120: 1547-1555.
14. Morgan JM, Griffiths M, du Bois RM, Evans TW: Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 1991; 99: 551-556.
15. Packer M, Lee WH, Medina N, Yushak M: Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders. Am J Cardiol 1986; 57: 853-858.
16. Sandoval J, Aguirre JS, Pulido T, et al: Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164: 1682-1687.
17. Bowyer JJ, Busst CM, Denison DM, Shinebourne EA: Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986; 55: 385-390.
18. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA: Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110: 710-717.
19. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
20. Broberg C, Ujita M, Babu-Narayan S, et al: Massive pulmonary artery thrombosis with haemoptysis in adults with Eisenmenger's syndrome: a clinical dilemma. Heart 2004; 90:e63.
21. Barst RJ, McGoon M, Torbicki A, et al: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-47S.
22. Recommendations on the management of pulmonary hypertension in clinical practice: Heart 2001; 86: 1i-13.
23. Denton CP, Black CM: Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003; 29: 335-349, vii.
24. Rich S, Seidlitz M, Dodin E, et al: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-792.
25. Morgan JM, McCormack DG, Griffiths MJ, et al: Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991; 84: 1145-1149.
26. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-2403.
27. Rich S, McLaughlin VV: The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1184-1187.
28. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
29. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
30. Badesch DB, Tapson VF, McGoon MD, et al: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-434.
31. Barst RJ, Maislin G, Fishman AP: Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.
32. Kong KO, Badsha H, Thumboo J, Chng HH: Intermittent epoprostenol infusions in systemic lupus erythematosus associated pulmonary hypertension -a series of three cases. Ann Acad Med Singapore 2003; 32: 118-121.
33. McLaughlin VV, Genthner DE, Panella MM, Rich S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
34. Takahashi T, Sakuma M, Ikeda J, et al: Effects and problems of continuous infusion of epoprostenol for patients with primary pulmonary hypertension. Intern Med 2002; 41: 784-788.
35. Sitbon O, Humbert M, Nunes H, et al: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
36. Higenbottam T, Siddons T: Trials of inhaled iloprost and other new vasodilating prostaglandins. Eur Respir J 2001; 17: 6-7.
37. Opitz CF, Wensel R, Bettmann M, et al: Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: 356-365.
38. McLaughlin VV, Gaine SP, Barst RJ, et al: Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 41: 293-299.
39. Vizza CD, Sciomer S, Morelli S, et al: Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001; 86: 661-665.
40. Barst RJ, McGoon M, McLaughlin V, et al: Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
41. Ono F, Nagaya N, Okumura H, et al: Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 2003; 123: 1583-1588.
42. Kesten S, Dainauskas J, McLaughlin V, Rich S: Development of nonspecific interstitial pneumonias associated with longterm treatment of primary pulmonary hypertension with prostacyclin. Chest 1999; 116: 566-569.
43. Hoeper MM, Olschewski H, Ghofrani HA, et al: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182.
44. Petros AJ, Turner SC, Nunn AJ: Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension. J Pharm Technol 1995; 11:163-166.
45. Beghetti M, Adatia I: Inhaled nitric oxide and congenital cardiac disease. Cardiol Young 2001; 11: 142-152.
46. Williamson DJ, Wallman LL, Jones R, et al: Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102: 411-418.
47. Sitbon O, Badesch DB, Channick RN, et al: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-254.
48. Galie N, Hinderliter AL, Torbicki A, et al: Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-1386.
49. Barst RJ, Ivy D, Dingemanse J, et al: Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-382.
50. Jasmin JF, Lucas M, Cernacek P, Dupuis J: Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 2001; 103: 314-318.
51. Apostolopoulou SC, Rammos S, Kyriakides ZS, et al: Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease. Heart 2003; 89: 1221-1226.
52. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121: 1860-1868.
53. Gratton JP, Cournoyer G, Loffler BM, Sirois P, D'Orleans-Juste P: ET(B) receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension 1997; 30: 1204-1209.
54. Reffelmann T, Kloner RA: Cardiovascular effects of sildenafil in experimental ischemia-reperfusion (reply to "Sildenafil-induced cardioprotection in rabbits, by Kukreja RC, Ockaili R, Salloum F, Xi L"). Cardiovasc Res 2003; 60: 702-703.
55. Zhao L, Mason NA, Morrell NW, et al: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424-428.
56. Abrams D, Schulze-Neick I, Magee AG: Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.
57. Ghofrani HA, Wiedemann R, Rose F, et al: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
58. Stiebellehner L, Petkov V, Vonbank K, et al: Long-term treatment with oral Sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123:1293-1295.
59. Ghofrani HA, Rose F, Schermuly RT, et al: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002; 30: 2489-2492.
60. Wilkens H, Guth A, Konig J, et al: Effect of inhaled iloprost plus oral Sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-1222.
61. Haznedaroglu IC, Atalar E, Ozturk MA, et al: Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension. Platelets 2002; 13: 395-399.
62. Eddahibi S, Morrell N, d'Ortho MP, Naeije R, Adnot S: Pathobiology of pulmonary arterial hypertension. Eur Respir J 2002; 20: 1559-1572.
63. Petkov V, Mosgoeller W, Ziesche R, et al: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111: 1339-1346.
64. Nagaya N, Miyatake K, Kyotani S, Nishikimi T, Nakanishi N, Kangawa K: Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension. Hypertens Res 2003; 26: S141-146.
65. Morris CR, Morris SM Jr, et al: Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168: 63-69.
66. Du L, Sullivan CC, Chu D, et al: Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003; 348: 500-509.
67. Cool CD, Rai PR, Yeager ME, et al: Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349: 1113-1122.
68. Arroliga AC, Sandur S, Jacobsen DW, et al: Association between hyperhomocysteinemia and primary pulmonary hypertension. Respir Med 2003; 97: 825-829.
69. Abraham WT, Raynolds MV, Badesch DB, et al: Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst 2003; 4: 27-30.
70. Rothman A, Sklansky MS, Lucas VW, et al: Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999; 84: 682-686.
71. Kurzyna M, Dabrowski M, Torbicki A, et al: Atrial septostomy for severe primary pulmonary hypertension - report on two cases. Kardiol Pol 2003; 58: 27-33.
72. Reichenberger F, Pepke-Zaba J. McNeil K, Parameshwar J, Shapiro LM: Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 2003; 58: 797-800.
73. Sandoval J, Rothman A, Pulido T: Atrial septostomy for pulmonary hypertension. Clin Chest Med 2001; 22: 547-560.
74. Jamieson SW, Nomura K: Indications for and the results of pulmonary thromboendarterectomy for thromboembolic pulmonary hypertension. Semin Vase Surg 2000; 13: 236-244.
75. Jamieson SW, Kapelanski DP, Sakakibara N, et al: Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76:1457-1462; discussion 1462-1464.
76. Nagaya N, Sasaki N, Ando M, et al: Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003; 123: 338-343.
77. Conte JV, Borja MJ, Patel CB, Yang SC, Jhaveri RM, Orens JB: Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg 2001; 72: 1673-1679; discussion 1679-1680.
78. Reichart B, Gulbins H, Meiser BM, Kur F, Briegel J, Reichenspurner H: Improved results after heart-lung transplantation: a 17-year experience. Transplantation 2003; 75: 127-132.
79. Franke U, Wiebe K, Harringer W, et al: Ten years experience with lung and heart-lung transplantation in primary and secondary pulmonary hypertension. Eur J Cardiothorac Surg 2000; 18: 447-452.
80. Charman SC, Sharpies LD, McNeil KD, Wallwork J: Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002; 21: 226-232.
81. Pielsticker EJ, Martinez FJ, Rubenfire M: Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant 2001; 20: 1297-1304.
82. Trulock EP: Lung transplantation for primary pulmonary hypertension. Clin Chest Med 2001; 22: 583-593.
83. Rosenzweig EB, Kerstein D, Barst RJ: Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-1865.
84. Gatzoulis MA, Rogers P, Li W, et al: Safety and tolerability of bosentan in adults with Eisenmenger physiology, Int J Card 2005; 98: 147-151.
85. Granton JT, Rabinovitch M: Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin 2002; 20: 441-457, vii.